Eli Lilly and Company
GLUCAGON-LIKE PEPTIDE1 RECEPTOR AGONISTS
Last updated:
Abstract:
In an embodiment, the present invention provides a compound of the formula: ##STR00001## or a pharmaceutically acceptable salt thereof, and methods of using this compound for treating type II diabetes mellitus.
Status:
Application
Type:
Utility
Filling date:
19 Jun 2020
Issue date:
31 Dec 2020